Allergic rhinitis. Vasomotor and allergic rhinitis
Conditions
Interventions
Intervention 1: Intervention group: Standard treatment consisted of an oral antihistamine (cetirizine), an oral leukotriene receptor antagonist (montelukast), and a nasal corticosteroid (mometasone) +
Sponsors
Oroumia University of Medical Sciences
Eligibility
Sex/Gender
All
Age
No minimum to 18 Years
Inclusion criteria
Inclusion criteria: Children under 18 years with allergic rhinitis Presence of allergic rhinitis symptoms (rhinorrhea, sneezing, nasal congestion, and itching of nose, eyes, throat, and palate) Moderate severity (symptoms =4 days per week or =4 consecutive weeks) or severe (symptoms with impaired sleep, school, or daily activities) according to ARIA criteria Written informed consent from parents or legal guardians for participation in the study
Exclusion criteria
Exclusion criteria: Non-allergic rhinitis Anatomical or obstructive nasal disorders (polyp, tumor, bacterial sinusitis, adenoid or tonsillar hypertrophy) Presence of asthma Presence of serious diseases such as kidney disease Use of potent systemic drugs such as oral corticosteroids Use of Vitamin D3 during the past six months Use of medications affecting serum Vitamin D levels (such as antiepileptics, metformin, diuretics, calcium channel blockers, etc) Intolerance to Vitamin D3 pearls Unwillingness to participate in the study or lack of informed consent from parents or legal guardians
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) score. Timepoint: Patient information forms will be completed at the baseline visit (week 0) and at 8 weeks, and the collected data will be compared thereafter. Method of measurement: Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ).;Total Nasal Symptom Score (TNSS). Timepoint: Patient information forms will be completed at the baseline visit (week 0) and at 8 weeks, and the collected data will be compared thereafter. Method of measurement: Total Nasal Symptom Score (TNSS) questionnaire. | — |
Secondary
| Measure | Time frame |
|---|---|
| Improvement in sleep quality. Timepoint: Patient information forms will be completed at the baseline visit (week 0) and at 8 weeks, and the collected data will be compared thereafter. Method of measurement: Self-reported.;Improvement in academic performance. Timepoint: Patient information forms will be completed at the baseline visit (week 0) and at 8 weeks, and the collected data will be compared thereafter. Method of measurement: Self-reported.;Relief of fatigue. Timepoint: Patient information forms will be completed at the baseline visit (week 0) and at 8 weeks, and the collected data will be compared thereafter. Method of measurement: Self-reported.;Alleviation of depressive symptoms. Timepoint: Patient information forms will be completed at the baseline visit (week 0) and at 8 weeks, and the collected data will be compared thereafter. Method of measurement: Self-reported. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public Contact??Dr. Hamid Reza Houshmand
Oroumia University of Medical Sciences
Outcome results
None listed